Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and Guanfacine for Heroin Addiction
NCT00142948Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2006
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone and guanfacine in heroin dependence (4 arms), sponsored by Baylor College of Medicine. Primary endpoint: Heroin relapse at 6 months. Started Feb 2006; status: completed.
02
Drugs
naltrexoneguanfacine
03
Conditions
heroin dependence
Beyond the preview
Go deeper on NCT00142948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142948.